At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 192 enrolled
Drug / intervention
TR-701 200 mg +2 moredrug
Likely dose
TR-701 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Multi-Center, Randomized, Double-Blind, Non-Controlled Study Comparing the Safety, Tolerance, and Efficacy of TR-701 in Patients With Complicated Skin and Skin Structure Infections
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)·interventional·Posted Sep 29, 2008·Updated Nov 25, 2019
In Brief
A Phase 2 clinical trial evaluating TR-701 200 mg, TR-701 300 mg, and 1 other intervention for Skin Diseases, Infectious and Skin Diseases, Bacterial. Completed, enrolled 192 participants across 12 sites.
Detailed Summary
The purpose of the study is to determine the oral dosage of TR-701 to be used in Phase III studies in patients with complicated skin and skin structure infections.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2008
First PostedSep 2008
Primary CompletionFeb 2009
TodayJul 2026
First PostedSep 29, 2008
Enrollment StartSep 17, 2008
Primary CompletionFeb 24, 2009
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 17.8 years ago
Interventions
TR-701 200 mgdrug
oral TR-701 200 mg for 5 to 7 days
TR-701 300 mgdrug
oral TR-701 300 mg for 5 to 7 days
TR-701 400 mgdrug
TR-701 400 mg for 5 to 7 days